title: Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
authors.affiliation: Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.
authors.forename: Sarbjit S
authors.initials: SS
authors.lastname: Saini
authors.affiliation: Genentech, Inc., South San Francisco, California, USA.
authors.forename: Theodore A
authors.initials: TA
authors.lastname: Omachi
authors.affiliation: Genentech, Inc., South San Francisco, California, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Trzaskoma
authors.affiliation: Genentech, Inc., South San Francisco, California, USA.
authors.forename: Henry N
authors.initials: HN
authors.lastname: Hulter
authors.affiliation: Genentech, Inc., South San Francisco, California, USA.
authors.forename: Karin
authors.initials: K
authors.lastname: Rosén
authors.affiliation: Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Sterba
authors.affiliation: Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, USA.
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Courneya
authors.affiliation: LabCorp Clinical Trials, Brentwood, Tennessee, USA.
authors.forename: Alan
authors.initials: A
authors.lastname: Lackey
authors.affiliation: Genentech, Inc., South San Francisco, California, USA. Electronic address: chenh37@gene.com.
authors.forename: Hubert
authors.initials: H
authors.lastname: Chen
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001491:Basophils / Q000502:physiology*; D002908:Chronic Disease; D006801:Humans; D007958:Leukocyte Count; D000069444:Omalizumab / Q000627:therapeutic use*; D011446:Prospective Studies; D014581:Urticaria / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
chemical_list: D018926:Anti-Allergic Agents; D000069444:Omalizumab